BAFF, inhibitors thereof and their use in the modulation of...

Details BAFF, inhibitors thereof and their use in the modulation of... BAFF, inhibitors thereof and their use in the modulation of...

2005-03-22

2005-03-22

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S145100, C424S177100, C530S388230, C530S389200

Reexamination Certificate

active

06869605

ABSTRACT:
The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.

REFERENCES:
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5969102 (1999-10-01), Bram et al.
patent: 6297367 (2001-10-01), Tribouley
patent: 6316222 (2001-11-01), Bram et al.
patent: 6475986 (2002-11-01), Aggarwal
patent: 6475987 (2002-11-01), Shu
patent: 6541224 (2003-04-01), Yu et al.
patent: 20030023038 (2003-01-01), Rennert et al.
patent: 0 869 180 (1998-10-01), None
patent: 0 921 194 (1999-06-01), None
patent: WO 9733902 (1997-09-01), None
patent: WO 9818921 (1998-05-01), None
patent: WO 9827114 (1998-06-01), None
patent: WO 9839361 (1998-09-01), None
patent: WO 9855620 (1998-12-01), None
patent: WO 9855621 (1998-12-01), None
patent: WO 9911791 (1999-03-01), None
patent: WO 9912964 (1999-03-01), None
patent: WO 9912965 (1999-03-01), None
patent: WO 9933980 (1999-07-01), None
patent: WO 0026244 (2000-05-01), None
patent: WO 0039295 (2000-07-01), None
patent: WO 0040716 (2000-07-01), None
patent: WO 0043032 (2000-07-01), None
patent: WO 0050597 (2000-08-01), None
patent: WO 0050633 (2000-08-01), None
patent: WO 0068378 (2000-11-01), None
patent: WO 0202641 (2002-01-01), None
patent: WO 0218620 (2002-03-01), None
patent: WO 03055979 (2003-07-01), None
Furie et al. Safety, Pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphoStat-B in SLE Patients. American College of Rheumatology (ACR), 67th Annual Scientific meeting, Abstract. 922, Oct. 23-28, 2003.*
Wendy et al. Effects of lymphoStat-B, a bLyS Antagonist, when Administered Intravenously to Cynomolgus Monkeys. American College of Rheumatology (ACR), 67thAnnual Scientific meeting, Abstract. 1537, Oct. 23-28, 2003.*
Kayagaki et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 17(4):515-524, 2002.*
Colman PM. Effects of amino acid sequence changes on antibody-antigen interactions. Res Immunol. 145(1):33-36, 1994.*
Ward PA, Mulligan MS. Blocking of adhesion molecules in vivo as anti-inflammatory therapy. Ther Immunol 1(3):165-171, 199.*
Harlow E, Lane D.. Antibodies a laboratory manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 198.*
Ware CF. APRIL and BAFF connect autoimmunity and cancer. J Exp Med. 192(11):F35-8, 2000.*
Kogan et al A single amino acid residue can determine the ligand specificity of E-selectin. J Biol Chem. 270(23):14047-55, 199.*
Gras et al., “BCMAp: An Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes”, International Immunology, vol. 7, No. 7, 1995, pp. 1093-1106.
Gross et al., “TACI and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease”, Nature, vol. 404, Apr. 27, 2000, pp. 995-999.
Hahne et al., “APRIL, A New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth”, J. Exp. Med., vol. 188, No. 6, Sep. 21, 1998, pp. 1185-1190.
Khare et al., “Severe B Cell Hyperplasia and Autoimmune Disease in TALL-1 Transgenic Mice”, Proceedings of the National Academy of Sciences of the United States of America, Mar. 28, 2000, vol. 97, No. 7, pp. 3370-3375.
Kwon et al., “Functions of Newly Identified Members of theTumor Necrosis Factor Receptor/Ligand Superfamilies in Lymphocytes”, Current Opinion in Immunology, 1999, pp. 340-345.
Laabi et al., “A New Gene, BCM, on Chromosome 16 is Fused to the Interleukin 2 Gene by a t(4;16) (q26;p13) Translocation in a Malignant T Cell Lymphoma”, The EMBO Journal, vol. 11, No. 11, 1992, pp. 3897-3904.
Laabi et al., “The BCMA Gene, Preferentially Expressed During B Lymphoid Maturation, is Bidirectionally Transcribed”, Nucleic Acids Research, vol. 22, No. 7, 1994, pp. 1147-1154.
MacKay et al., “Mice Transgenic for BAFF Develop Lymphocytic Disorders along with Autoimmune Manifestations”, Journal of Experimental Medicine, Dec. 6, 1999, vol. 190, No. 11, pp. 1697-1710.
Maldry et al., “The Characterization of Murine BCMA Gene Defines it as a New Memer of the Tumor Necrosis Factor Receptor Superfamily”, International Immunology, vol. 10, No. 11, 1998, pp. 1693-1702.
Mukhopadhyay et al., “Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue that Activates Apoptosis, Nuclear Factor-kappaB, and c-Jun NH2-Terminal Kinase”, Journal of Biological Chemistry, Jun. 4, 1999, vol. 274, No. 23, pp. 15978-15981.
Moore et al., “BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator”, Science, Jul. 9, 1999, vol. 285, No. 5425, pp. 260-263.
Pitti et al., “Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer”, Nature, vol. 396, Dec. 17, 1998, pp. 699-703.
Schneider et al., “BAFF, A Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth”, J. Exp. Med., vol. 189, No. 11, Jun. 7, 1999, pp. 1747-1756.
Shu et al., “B Cell Maturation Protein is a Receptor for the Tumor Necrosis Factor Family Member TALL-1”, PNAS, vol. 97, No. 16, Aug. 1, 2000, pp. 9156-9161.
Thompson et al., “BAFF Interacts with the Orphan Receptor, BCMA”, Scandinavian Journal of Immunology, vol. 51 (Supplement 1), 2000, p. 65.
Thompson et al., “BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population”, J. Exp. Med., vol. 192, No. 1, Jul. 3, 2000, pp. 129-135.
Xia et al., “TACI is a TRAF-Interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation”, J. Exp. Med., vol. 192, No. 1, Jul. 3, 2000, pp. 137-143.
Yu et al., “APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity”, Nature Immunology, vol. 1, No. 3, Sep. 2000, pp. 252-256.
Kashii, Y. et al., “Constitutive Expression and Role of the TNF Family Ligands in Apoptotic Killing of Tumor Cells by Human Ink Cells,”J. Immunol. 163:5358-66 (1999).
Published U.S. Appl. No. 10/380,703, filed Mar. 17, 2003; Publication No. US-2004-0072188-A1, published Apr. 15, 2004.
Published U.S. Appl. No. 10/077,438, filed Feb. 15, 2002; Publication No. US-2002-0165156-A1, published Nov. 7, 2002.
Published U.S. Appl. No. 10/077,137, filed Feb. 15, 2002; Publication No. US-2002-0172674-A1, published Nov. 21, 2002.
Published U.S. Appl. No. 10/115,192, filed Apr. 2, 2002; Publication No. US-2003-0082175-A1, published May 1, 2003.
Published U.S. Appl. No. 10/214,065, filed Aug. 7, 2002; Publication No. US 2003-0023038-A1, published Jan. 30, 2003.
Published U.S. Appl. No. 10/258,368, filed Jun. 23, 2003; Publication No. US-2004-0013674-A1, published Jan. 22, 2004.

Affiliated with

Also associated with

Rating

BAFF, inhibitors thereof and their use in the modulation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BAFF, inhibitors thereof and their use in the modulation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BAFF, inhibitors thereof and their use in the modulation of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3391365